Table 4.
Comparison of clinical information based on VTE occurrence.
| Clinical information | OR (Univariate Analysis) | OR (Multivariate Analysis) |
|---|---|---|
| Age (y) | 1.35 | 1.92 |
| Gender (female) | 0.98 | 4.05 |
| Anticoagulation therapy | 0.01 | 0.02 |
| Tumor volume (cm2) | 1.13 | 2.27 |
| Tumor gradea | 518.79 | 697.12 |
| Gene expression | ||
| IDH1 MUT | 0.32 | 0.06 |
| EGFR+ | 1.93 | 7.38 |
| MGMT Methylation | 0.49 | 0.12 |
| p53 MUT | 4.34 | 7.97 |
| Treatment | ||
| Radiotherapy | 0.61 | 0.59 |
| Chemotherapy | 0.21 | 0.12 |
| Target therapies | 0.94 | 0.80 |
| Chinese traditional medicinE | 0.88 | 0.89 |
| Prolonged bed restb | 0.36 | 0.01 |
| Glucocorticoid therapy | 9.41 | 6.24 |
| History of CVCP | 40.27 | 0.86 |
VTE, venous thromboembolism; IDH MUT, isocitrate dehydrogenase mutation; ATRX +, alpha-thalassemia/mental retardation syndrome X-linked positive; EGFR +, epidermal growth factor receptor positive; MGMT, O6-methylguanine-DNA methyltransferase; p53, tumor protein p53; CVCP, central venous catheter placement.
a
According to the retained pathological reports.
b
Bed rest for more than 2 weeks.